Asia-Pacific Journal of Ophthalmology最新文献

英文中文

Slanted versus conventional bilateral lateral rectus recession in children with convergence insufficiency intermittent exotropia: A multicentre, randomized trial 斜向与常规双侧直肌衰退对收敛不全间歇性外斜视儿童的影响：一项多中心随机试验。

IF 4.5 3区医学 Q1 OPHTHALMOLOGY

Asia-Pacific Journal of Ophthalmology

Pub Date : 2026-01-01 DOI: 10.1016/j.apjo.2026.100275

Jing Yao , Xiying Wang , Chenhao Yang , Lingyan Dong , Jiangtao Xu , Xiaojun Ren , Chao Jiang , Wenqing Zhu , Rongmei Zhou , Tienan Feng , Jie Hong , Hu Liu , Lianhong Zhou , Lihua Wang , Junhong Li , Xiaoli Kang , Yueping Li , Wei Zhang , Kanxing Zhao , Chen Zhao

Purpose

To assess the efficacy of slanted bilateral lateral rectus recession (S-BLR) versus conventional bilateral lateral rectus recession (C-BLR) in children with convergence insufficiency intermittent exotropia (CI-IXT).

Design

Multicentre, randomized controlled trial.

Methods

Chinese children aged 5–12 years with CI-IXT were consecutively enrolled, and randomly assigned (1:1) to receive either S-BLR or C-BLR. The primary outcome was the 12-month overall success rate, defined as a postoperative residual deviation between 10Δ of exodeviation and 5Δ of esodeviation with near-distance disparity (NDD) < 10Δ.

Results

A total of 200 participants were enrolled, and 188 (97 S-BLR, 91 C-BLR) were finally included in the modified intention-to-treat analysis. The median age was 8 (6−9) years, and 90 (48 %) were male. The 12-month overall success rates did not differ significantly between the groups (group difference 8 %, P = 0.27, adjusted P = 0.36). However, S-BLR exhibited a lower rate of near undercorrection (group difference −12 %, P = 0.06), more collapse of NDD (-2.00^Δ, P = 0.001), less residual near exodeviation (-4.00^Δ, P < 0.001), better control of near exodeviation (0.00, P = 0.01), and a higher proportion of improved stereoacuity (12 %, P = 0.06). Subgroup analysis for NDD≤ 15^Δ revealed a higher success rate of near deviation (86 % versus 69 %, P = 0.02), and a lower rate of near undercorrection (13 % versus 30 %, P = 0.01) in S-BLR group. Aside from undercorrection and overcorrection, no additional long-term suboptimal surgical outcomes were observed.

Conclusions

Although the overall success rates did not differ, S-BLR showed potential superiority at near in children with CI-IXT. More participants with NDD> 15^Δ, and a longer follow-up are needed to validate these findings.

目的：评价斜向双侧直肌收缩术（S-BLR）与常规双侧直肌收缩术（C-BLR）治疗会敛功能不全儿童间歇性外斜视（CI-IXT）的疗效。设计：多中心、随机对照试验。方法：连续入组5-12岁CI-IXT患儿，按1:1比例随机分为S-BLR组和C-BLR组。主要结果是12个月的总成功率，定义为10Δ外偏和5Δ内偏之间的术后剩余偏差与近距离差异（NDD）。结果：总共有200名参与者入组，188名（97名S-BLR， 91名C-BLR）最终被纳入改进的意向治疗分析。中位年龄为8岁（6-9岁），男性90例（48%）。组间12个月总成功率无显著差异（组间差异8%，P = 0.27，调整后P = 0.36）。然而，S-BLR表现出较低的近矫正不足率（组差-12%，P= 0.06），更多的NDD塌陷（-2.00Δ， P= 0.001），更少的残余近外偏差（-4.00Δ， P < 0.001），更好的控制近外偏差（0.00，P=0.01）和更高的立体视力改善比例（12%，P= 0.06）。NDD≤15Δ的亚组分析显示，S-BLR组的近偏差成功率较高（86%对69%，P = 0.02），近欠校正率较低（13%对30%，P = 0.01）。除矫正不足和矫正过度外，未观察到其他长期次优手术结果。结论：虽然总体成功率没有差异，但S-BLR在CI-IXT患儿中显示出潜在的优势。需要更多患有NDD>15Δ的参与者和更长的随访来验证这些发现。

{"title":"Slanted versus conventional bilateral lateral rectus recession in children with convergence insufficiency intermittent exotropia: A multicentre, randomized trial","authors":"Jing Yao , Xiying Wang , Chenhao Yang , Lingyan Dong , Jiangtao Xu , Xiaojun Ren , Chao Jiang , Wenqing Zhu , Rongmei Zhou , Tienan Feng , Jie Hong , Hu Liu , Lianhong Zhou , Lihua Wang , Junhong Li , Xiaoli Kang , Yueping Li , Wei Zhang , Kanxing Zhao , Chen Zhao","doi":"10.1016/j.apjo.2026.100275","DOIUrl":"10.1016/j.apjo.2026.100275","url":null,"abstract":"<div><h3>Purpose</h3><div>To assess the efficacy of slanted bilateral lateral rectus recession (S-BLR) versus conventional bilateral lateral rectus recession (C-BLR) in children with convergence insufficiency intermittent exotropia (CI-IXT).</div></div><div><h3>Design</h3><div>Multicentre, randomized controlled trial.</div></div><div><h3>Methods</h3><div>Chinese children aged 5–12 years with CI-IXT were consecutively enrolled, and randomly assigned (1:1) to receive either S-BLR or C-BLR. The primary outcome was the 12-month overall success rate, defined as a postoperative residual deviation between 10Δ of exodeviation and 5Δ of esodeviation with near-distance disparity (NDD) < 10Δ.</div></div><div><h3>Results</h3><div>A total of 200 participants were enrolled, and 188 (97 S-BLR, 91 C-BLR) were finally included in the modified intention-to-treat analysis. The median age was 8 (6−9) years, and 90 (48 %) were male. The 12-month overall success rates did not differ significantly between the groups (group difference 8 %, <em>P</em> = 0.27, adjusted <em>P</em> = 0.36). However, S-BLR exhibited a lower rate of near undercorrection (group difference −12 %, <em>P</em> = 0.06), more collapse of NDD (-2.00<sup>Δ</sup>, <em>P</em> = 0.001), less residual near exodeviation (-4.00<sup>Δ</sup>, <em>P</em> < 0.001), better control of near exodeviation (0.00, <em>P</em> = 0.01), and a higher proportion of improved stereoacuity (12 %, <em>P</em> = 0.06). Subgroup analysis for NDD≤ 15<sup>Δ</sup> revealed a higher success rate of near deviation (86 % versus 69 %, <em>P</em> = 0.02), and a lower rate of near undercorrection (13 % versus 30 %, <em>P</em> = 0.01) in S-BLR group. Aside from undercorrection and overcorrection, no additional long-term suboptimal surgical outcomes were observed.</div></div><div><h3>Conclusions</h3><div>Although the overall success rates did not differ, S-BLR showed potential superiority at near in children with CI-IXT. More participants with NDD> 15<sup>Δ</sup>, and a longer follow-up are needed to validate these findings.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 1","pages":"Article 100275"},"PeriodicalIF":4.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145942361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A suspended anterior chamber nematode: Novel ivcm imaging of parasitic architecture 悬浮前房线虫：寄生结构的新型ivcm成像。

IF 4.5 3区医学 Q1 OPHTHALMOLOGY

Asia-Pacific Journal of Ophthalmology

Pub Date : 2026-01-01 DOI: 10.1016/j.apjo.2025.100251

Xinhan Cui , Ning Lyu , Jun Xiang

引用次数: 0

Oculomics and AI: The eye as a biomarker for health span 眼科和人工智能：眼睛作为健康跨度的生物标志物。

IF 4.5 3区医学 Q1 OPHTHALMOLOGY

Asia-Pacific Journal of Ophthalmology

Pub Date : 2026-01-01 DOI: 10.1016/j.apjo.2026.100282

Joy Le Yi Wong , Haoran Cheng , Wen Jun Peh , Dean Ho , Tien Y. Wong , Celene Yan Yan Hui , Darren S.J. Ting , Yong Mong Bee , Su Yen Goh , Rajendra S. Apte , Vinit B. Mahajan , Jeffrey L. Goldberg , Evelyne Bischof , David A. Sinclair , Carol C. Cheung , Hiok Hong Chan , Kanae Fukutsu , Ting Fang Tan , Chrystie Wan Ning Quek , Ashley Shuen Ying Hong , Daniel S.W. Ting

As the world’s population ages, the focus of healthcare is shifting from extending life span to promoting health span. There is an unmet need to identify sensitive and reliable markers of health span through more cost-effective and non-invasive methods, to enable early and effective intervention on modifiable aging factors. The eye offers a unique window into systemic health, providing direct visualization of the body’s vascular and neural health. This review presents an overview of how various ocular structures can serve as biomarkers of health span—drawing on insights from ocular imaging, metabolomics, and proteomics, with evidence from basic science, animal models, and human clinical trials. The role of artificial intelligence (AI) in predicting biological age and the risk of age-related systemic conditions is also highlighted, with a focus on current applications and how AI is being integrated to synthesize and interpret multimodal data.

随着世界人口老龄化，医疗保健的重点正从延长寿命转向促进健康寿命。通过更具成本效益和非侵入性的方法确定敏感和可靠的健康跨度标志，以便能够对可改变的衰老因素进行早期和有效的干预，这一需求尚未得到满足。眼睛为观察全身健康提供了一个独特的窗口，提供了对身体血管和神经健康的直接可视化。这篇综述概述了各种眼部结构如何作为健康跨度的生物标志物，利用眼部成像、代谢组学和蛋白质组学的见解，以及基础科学、动物模型和人体临床试验的证据。还强调了人工智能（AI）在预测生物年龄和与年龄相关的系统性疾病风险方面的作用，重点是当前的应用以及如何将人工智能集成到综合和解释多模态数据中。

{"title":"Oculomics and AI: The eye as a biomarker for health span","authors":"Joy Le Yi Wong , Haoran Cheng , Wen Jun Peh , Dean Ho , Tien Y. Wong , Celene Yan Yan Hui , Darren S.J. Ting , Yong Mong Bee , Su Yen Goh , Rajendra S. Apte , Vinit B. Mahajan , Jeffrey L. Goldberg , Evelyne Bischof , David A. Sinclair , Carol C. Cheung , Hiok Hong Chan , Kanae Fukutsu , Ting Fang Tan , Chrystie Wan Ning Quek , Ashley Shuen Ying Hong , Daniel S.W. Ting","doi":"10.1016/j.apjo.2026.100282","DOIUrl":"10.1016/j.apjo.2026.100282","url":null,"abstract":"<div><div>As the world’s population ages, the focus of healthcare is shifting from extending life span to promoting health span. There is an unmet need to identify sensitive and reliable markers of health span through more cost-effective and non-invasive methods, to enable early and effective intervention on modifiable aging factors. The eye offers a unique window into systemic health, providing direct visualization of the body’s vascular and neural health. This review presents an overview of how various ocular structures can serve as biomarkers of health span—drawing on insights from ocular imaging, metabolomics, and proteomics, with evidence from basic science, animal models, and human clinical trials. The role of artificial intelligence (AI) in predicting biological age and the risk of age-related systemic conditions is also highlighted, with a focus on current applications and how AI is being integrated to synthesize and interpret multimodal data.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 1","pages":"Article 100282"},"PeriodicalIF":4.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Envisioning the future: Ever-increasing quality of the journal 展望未来：期刊质量不断提高。

IF 4.5 3区医学 Q1 OPHTHALMOLOGY

Asia-Pacific Journal of Ophthalmology

Pub Date : 2026-01-01 DOI: 10.1016/j.apjo.2026.100281

Jost B. Jonas, Dennis S.C. Lam

引用次数: 0

A rare case of caruncular actinomycosis presenting with tumor-like features 一例少见的环形放线菌病表现为肿瘤样特征。

IF 4.5 3区医学 Q1 OPHTHALMOLOGY

Asia-Pacific Journal of Ophthalmology

Pub Date : 2026-01-01 DOI: 10.1016/j.apjo.2025.100202

Tatsuya Sakamoto, Kentaro Sueoka, Taiichiro Chikama

引用次数: 0

Descemet membrane endothelial keratoplasty under failed sclerocorneal transplantation 硬角膜移植失败下的内皮膜角膜移植术。

IF 4.5 3区医学 Q1 OPHTHALMOLOGY

Asia-Pacific Journal of Ophthalmology

Pub Date : 2026-01-01 DOI: 10.1016/j.apjo.2025.100220

Thibaud Garcin, Mathilde Kaspi, Nacim Bouheraoua, Vincent Borderie

引用次数: 0

Retinal toxicity after intracameral cefuroxime following cataract surgery 白内障手术后头孢呋辛内窥镜后的视网膜毒性。

IF 4.5 3区医学 Q1 OPHTHALMOLOGY

Asia-Pacific Journal of Ophthalmology

Pub Date : 2026-01-01 DOI: 10.1016/j.apjo.2025.100206

Xuejuan Cheng , Lu Qiu , Fei Cong , Lei Gao

引用次数: 0

Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial 亚洲新生血管性年龄相关性黄斑变性患者玻璃体内注射阿布西普8mg vs 2mg: PULSAR试验3期48周分析

IF 4.5 3区医学 Q1 OPHTHALMOLOGY

Asia-Pacific Journal of Ophthalmology

Pub Date : 2026-01-01 DOI: 10.1016/j.apjo.2026.100278

Andrew Chang , Xiaodong Sun , Tomohiro Iida , Timothy Y.Y. Lai , Tien Y. Wong , Chui Ming Gemmy Cheung , Won Ki Lee , Xin Zhang , Andrea Schulze , Ursula Maria Schmidt-Ott , Min Zhao , Zoran Hasanbasic , Sergio Leal , Shih-Jen Chen , on behalf of the PULSAR study investigators

Purpose

To evaluate 1-year efficacy and safety of aflibercept 8 mg in Asian patients with neovascular age-related macular degeneration (nAMD) in the PULSAR (NCT04423718) trial.

Design

Subgroup analysis of the Phase 3 PULSAR trial.

Methods

Patients aged ≥ 50 years with nAMD were randomized to receive intravitreal aflibercept 8 mg every 12 (8q12) or 16 (8q16) weeks, or aflibercept 2 mg every 8 weeks (2q8), following 3 initial monthly injections. Outcomes included change from baseline in best-corrected visual acuity (BCVA) and central subfield retinal thickness (CRT), durability, and safety at week (W) 48.

Findings

Overall, 234 Asian patients participated and received study treatment (8q12 [n = 74], 8q16 [n = 77], and 2q8 [n = 83]). At W48, the least squares (LS) mean (95 % CI) BCVA change from baseline was + 9.9 (6.9, 12.9), + 9.2 (7.1, 11.2), and + 7.6 (4.7, 10.5) letters in the 8q12, 8q16, and 2q8 groups, respectively. The LS mean (95 % CI) change in CRT from baseline to W48 for the 8q12, 8q16, and 2q8 groups was −141 (−152, −129), −156 (−167, −146), and −142 (−155, −129) µm, respectively. Most patients receiving 8q12 (85 %) or 8q16 (87 %), maintained their randomized dosing interval, through W48. The safety profile of aflibercept 8 mg was comparable to aflibercept 2 mg.

Conclusions

Aflibercept 8 mg was effective and well tolerated in Asian patients with nAMD, with demonstrated improvements in functional and anatomic outcomes comparable to aflibercept 2 mg at W48. Aflibercept 8 mg outcomes were achieved with fewer injections than with aflibercept 2 mg, consistent with overall PULSAR results.

目的：在PULSAR （NCT04423718）试验中评估阿非利赛普8mg治疗亚洲新生血管性年龄相关性黄斑变性（nAMD）患者1年的疗效和安全性。设计：3期PULSAR试验的亚组分析。方法：年龄≥50岁的nAMD患者随机接受每12周（8q12）或16周（8q16）周玻璃体内注射阿非利塞普8mg，或每8周（2q8）注射阿非利塞普2mg，最初每月注射3次。结果包括第48周最佳矫正视力（BCVA）和中央亚视野视网膜厚度（CRT）、耐久性和安全性从基线的变化。结果：总体而言，234名亚洲患者参与并接受了研究治疗（8q12 [n = 74], 8q16 [n = 77], 2q8 [n = 83]）。在W48时，8q12、8q16和2q8组的最小二乘（LS）均值（95% CI） BCVA较基线变化分别为+9.9（6.9,12.9）、+9.2（7.1,11.2）和+7.6（4.7,10.5）个字母。8q12、8q16和2q8组CRT从基线到W48的LS平均值（95% CI）变化分别为-141（-152,-129）、-156（-167,-146）和-142（-155,-129）µm。大多数接受8q12（85%）或8q16（87%）治疗的患者在W48期间维持其随机给药间隔。阿伯西普8mg的安全性与阿伯西普2mg相当。结论：阿非利西普8mg对亚洲nAMD患者有效且耐受性良好，与阿非利西普2mg在W48时相比，在功能和解剖结果方面有明显改善。与阿非利西普2mg相比，阿非利西普8mg的注射次数更少，与总体PULSAR结果一致。

{"title":"Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial","authors":"Andrew Chang , Xiaodong Sun , Tomohiro Iida , Timothy Y.Y. Lai , Tien Y. Wong , Chui Ming Gemmy Cheung , Won Ki Lee , Xin Zhang , Andrea Schulze , Ursula Maria Schmidt-Ott , Min Zhao , Zoran Hasanbasic , Sergio Leal , Shih-Jen Chen , on behalf of the PULSAR study investigators","doi":"10.1016/j.apjo.2026.100278","DOIUrl":"10.1016/j.apjo.2026.100278","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate 1-year efficacy and safety of aflibercept 8 mg in Asian patients with neovascular age-related macular degeneration (nAMD) in the PULSAR (NCT04423718) trial.</div></div><div><h3>Design</h3><div>Subgroup analysis of the Phase 3 PULSAR trial.</div></div><div><h3>Methods</h3><div>Patients aged ≥ 50 years with nAMD were randomized to receive intravitreal aflibercept 8 mg every 12 (8q12) or 16 (8q16) weeks, or aflibercept 2 mg every 8 weeks (2q8), following 3 initial monthly injections. Outcomes included change from baseline in best-corrected visual acuity (BCVA) and central subfield retinal thickness (CRT), durability, and safety at week (W) 48.</div></div><div><h3>Findings</h3><div>Overall, 234 Asian patients participated and received study treatment (8q12 [n = 74], 8q16 [n = 77], and 2q8 [n = 83]). At W48, the least squares (LS) mean (95 % CI) BCVA change from baseline was + 9.9 (6.9, 12.9), + 9.2 (7.1, 11.2), and + 7.6 (4.7, 10.5) letters in the 8q12, 8q16, and 2q8 groups, respectively. The LS mean (95 % CI) change in CRT from baseline to W48 for the 8q12, 8q16, and 2q8 groups was −141 (−152, −129), −156 (−167, −146), and −142 (−155, −129) µm, respectively. Most patients receiving 8q12 (85 %) or 8q16 (87 %), maintained their randomized dosing interval, through W48. The safety profile of aflibercept 8 mg was comparable to aflibercept 2 mg.</div></div><div><h3>Conclusions</h3><div>Aflibercept 8 mg was effective and well tolerated in Asian patients with nAMD, with demonstrated improvements in functional and anatomic outcomes comparable to aflibercept 2 mg at W48. Aflibercept 8 mg outcomes were achieved with fewer injections than with aflibercept 2 mg, consistent with overall PULSAR results.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 1","pages":"Article 100278"},"PeriodicalIF":4.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145948525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Choroidal myeloid sarcoma as the initial manifestation of acute myeloid leukemia. 脉络膜髓系肉瘤为急性髓系白血病的首发表现。

IF 4.5 3区医学 Q1 OPHTHALMOLOGY

Asia-Pacific Journal of Ophthalmology

Pub Date : 2025-11-11 DOI: 10.1016/j.apjo.2025.100263

Yidong Wu, Xuemei Zhang, Carol L Shields, Xiaolu Yang

引用次数: 0

Postoperative endophthalmitis rate associated with routine off-label reuse of single-use phacoemulsification cassettes in more than 1,000,000 consecutive surgeries 在超过100万例连续手术中，术后眼内炎发生率与常规超说明书重复使用一次性超声乳化盒相关。

IF 4.5 3区医学 Q1 OPHTHALMOLOGY

Asia-Pacific Journal of Ophthalmology

Pub Date : 2025-11-01 DOI: 10.1016/j.apjo.2025.100247

David F. Chang , Aravind Haripriya

According to a 2025 APAO survey, reuse of phacoemulsification tubing and cassettes appears to be more common in Asian-Pacific countries compared to Europe and North America. We analyzed the phacoemulsification postoperative endophthalmitis (POE) rate from 2016 to 2024 at the Aravind Eye Care System’s 15 hospital network. Single-use phacoemulsification cassettes were routinely reused all day (off label) at every facility during this 9-year period. The POE rate was 0.01 % in 1,133,959 consecutive cases. This rate was consistent from year to year and compared favorably with contemporaneous POE data from the American Academy of Ophthalmology Intelligent Research in Sight (IRIS) Registry (0.06 %), where presumably no reuse of phacoemulsification cassettes would have been allowed. We found no evidence that reusing the same phacoemulsification tubing and cassette all day increased the rate of POE.

根据2025年APAO的一项调查，与欧洲和北美相比，重复使用超声乳化术管和盒在亚太国家似乎更为普遍。我们分析了2016年至2024年在Aravind眼科保健系统的15家医院网络中超声乳化术术后眼内炎（POE）的发生率。在这9年期间，在每个设施中，一次性超声乳化盒都被常规地全天重复使用（标签外）。在连续1133959个案例中，POE率为0.01%。这一比率每年都是一致的，并且与同期美国眼科智能研究中心（IRIS）登记的POE数据（0.06%）相比是有利的，后者可能不允许重复使用超声乳化盒。我们没有发现整天重复使用相同的超声乳化管和超声乳化盒会增加POE发生率的证据。

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Asia-Pacific Journal of Ophthalmology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀